Enasidenib for the treatment of cholangiocarcinoma

Enasidenib (Enasidenib) is an IDH2 inhibitor mainly used to treat specific hematological diseases, such as certain types of myelodysplastic syndromes and acute myeloid leukemia. The effectiveness of ensidipine in the treatment of cholangiocarcinoma has not yet been proven. Cholangiocarcinoma is a malignant tumor that usually requires comprehensive treatment options, including surgical resection, chemotherapy, radiotherapy, targeted therapy, etc. Specific treatment options should be determined by a physician based on the patient's condition and individualized assessment.

In a clinical study looking at the efficacy of ensidipine in acute myeloid leukemia, 50% of patients had a first response at 1.9 months, but 50% took longer. Half of the patients also saw their best response to ensidipine after taking it for 3.7 months, while half took longer. Overall, in clinical studies looking at the effects of ensidipine, 46 of 199 patients (23%) were found to be effective. Of the 214 patients evaluated for safety, half took ensidipine for more than 4.3 months, while the other half took it for less.

Ensiidi plain investigational medicine is not currently on the market in the country, nor is it covered by medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic encidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*60 tablets produced by a Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of the original encidipine generic drug.